SIRO Clinpharm and Advanced Clinical Trial Solutions Sign Strategic Alliance
Princeton, NJ, April 17, 2009: SIRO ClinPharm (SIRO), a leading multinational Contract Research Organization (CRO), today announced the signing of a strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, NJ, USA, a service provider in oncology drug development with a business concentration in North America. This alliance will enable SIRO to expand its oncology clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO’s clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.
“We are delighted to add ACT Solution’s North American expertise in our service offering to our customers, said Dr Chetan Tamhankar, COO of SIRO ClinPharm group. “This alliance is the first step for Siro in creating delivery capabilities in North America.”
“We are excited about aligning our strengths in oncology with SIRO’s international delivery capabilities,” said Patricia Devitt Risse, Pharm. D, President of ACT Solutions LLC . “This step addresses the changing dynamics of the clinical research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India,” she explained.
According to Patricia Terek, President of SIRO ClinPharm, USA, “This step will help meet the growing needs of our oncology customers to have access to operational capabilities in North America. We are excited to offer the clinical development expertise of ACT Solutions in North America to our customers globally.”
About SIRO SIRO is a leading multinational contract research organization. With a presence in over 15 countries across North America, Europe and Asia, SIRO offers global bio-technology and pharmaceutical companies end to end clinical trial services. Established in year 1996, SIRO has emerged as a leading name for high speed and optimal cost of conducting clinical research. More information about the SIRO group is available at www.siroclinpharm.com About Advanced Clinical Trial Solutions LLC
Advanced Clinical Trial Solutions LLC (ACT Solutions.) is a privately held company that is devoted to operational excellence in global oncology drug development. ACT Solutions is staffed solely with experienced oncology personnel that has enabled it to grow its business annually and to establish strategic partnerships to expand the scope of the ACT Solutions service offerings. . More information about ACT Solutions is available at www.actsolutions.org
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
